Effect of topical phenylephrine on aqueous flare levels and anterior scleral thickness in healthy adult eyes Authors: Mine Esen Baris, Azad Guclu, Suzan Guven, Melis Palamar Published: 2026 ABSTRACT BackgroundPhenylephrine is widely used for pharmacological mydriasis in routine ophthalmic practice. While its vascular and pupillary effects are well established, its influence on anterior segment structures and intraocular inflammatory parameters remains unclear. This study aimed to evaluate the effects of topical phenylephrine on anterior scleral thickness (AST) and aqueous humor flare levels in healthy eyes.MethodsThis prospective study included the right eyes of 20 healthy volunteers. Topical phenylephrine 2.5% was administered three times at 5-minute intervals. Measurements were obtained 45 min after the final instillation. Nasal and temporal AST were measured at the scleral spur (AST-0) and at 1000 μm (AST-1) and 2000 μm (AST-2) posterior to the scleral spur using anterior segment optical coherence tomography. Aqueous flare levels were assessed using laser flare photometry. Fellow untreated eyes served as controls.ResultsAt the scleral spur level (AST-0), scleral thickness increased significantly in both nasal and temporal regions following phenylephrine administration (p = 0.0003 and p = 0.01, respectively). At 1000 μm posterior to the scleral spur, temporal AST decreased significantly (p = 0.005), while other changes in AST-1 and AST-2 were not statistically significant. Aqueous flare levels showed an increase after phenylephrine instillation; however, this change was not statistically significant (p = 0.2). No significant changes were observed in the fellow control eyes.ConclusionsTopical phenylephrine was associated with localized changes in anterior scleral thickness, characterized by thickening at the scleral spur and relative thinning posteriorly. Although aqueous flare levels tended to increase, this effect was not statistically significant and likely reflects a minimal effect size. These findings suggest that phenylephrine may be associated with alterations in scleral configuration without a clinically meaningful impact on intraocular inflammatory status in healthy eyes. Introduction Phenylephrine is a sympathomimetic drug that is used for pupillary dilatation, commonly in combination with other cycloplegic and mydriatic drugs such as cyclopentolate, homatropin and tropicamide which are parasympathomimetics [1]. Both mydriasis and cycloplegia are essential parts of ophthalmological examination and pre-operative preparation for cataract surgery as well as treatment regimes such as uveitis. Atropine, the gold standard of cycloplegic refraction examination, is associated with long-lasting side effects and poor patient tolerence. Cyclopentolate 1% is the most commonly used cycloplegic agent with strong effect of relaxing the ciliary muscle and providing a reasonable dilatation. Even though its use for pediatric ophthalmological examination is considered as safe due to its transient adverse effects which are usually mild, serious systemic side effects were also reported from seizures to hallucinations or even psychosis. About 15% of patients between 0 and 15 years old are reported to experience a systemic or an ocular adverse effect of cyclopentolate 1% [2]. Each of these agents have different strengths and side effects. Therefore they are usually used in combination but there is still not a consensus on which combination is the best and the most effective for refractive examination. It is also known that pharmacological pupillary dilatation and mydriasis alters the aqueous humor protein concentrations. This is mostly important in uveitic eyes, in which mydriatics are used for treatment and the aqueous humor protein levels are important during follow up, to assess the activation of inflammation or response to treatment. This study aims to evaluate the effects of phenylephrine 2.5% eye drops on scleral thickness and aqueous humor flaremeter results. To the best of our knowledge, this is the first study to evaluate the effects of topical phenylephrine on anterior scleral thickness in vivo, together with its potential impact on aqueous humor flare levels. Materials and methods This prospective study was conducted in Ege University Ophthalmology Department between March 2024 and June 2024. Healthy volunteers older than 18 years and younger than 45 years of age with no known systemic and ocular diseases were included. Participants who had any systemic or ocular diseases, taking any systemic medications and/or vitamin supplements, using any type of eye-drops including artificial tears, and patients using contact lenses were excluded from the study. Eyes with high refractive errors ( > ± 3.0 D spheric and ± 1.0 D cylindric) or abnormal axial length (< 22 mm and > 24 mm) were also excluded. The ethics committee approval was obtained from Ege University Clinical Studies Ethics Committee. Written informed consent was gathered from all participants. The study was conducted in accordance with the principles of Declaration of Helsinki. All participants underwent a complete ophthalmological examination [best corrected visual acuity (BCVA) measurement using Snellen chart, intraocular pressure (IOP) measurement with Goldmann applanation tonometer, biomicroscobic anterior segment and fundus examinations] and anterior segment optical coherence tomography (AS-OCT, Topcon, Triton, Tokyo Japan) images were taken. Also anterior chamber aqueous flare (ACAF) levels were measured with laser flare meter (Kowa FM 600, Kowa Company Ltd, Nagoya, Japan) before phenylephrine 2.5% application. Topical phenylephrine 2.5% eye drops (Mydfrin®, Alcon, Texas, USA) were applied on the right eyes of each participant and both AS-OCT and ACAF were repeated 45 min after the last drop of three consecutive instillation of the phenylephrine 2.5% eye drops applied between five minutes intervals. Left eyes were included as the control group. The fellow untreated eye was used as a control to minimize inter-individual variability in anatomical and physiological parameters, allowing for within-subject comparison under identical systemic conditions. Three AS-OCT scans were obtained for both pre- and post-phenylephrine application and the images with the highest quality were used for analysis. Only images with signal strength intensity higher than 41 were used. For nasal and temporal AST measurements, the participants were asked to look at the respective directions. Nasal and temporal anterior scleral thicknesses were measured manually from the pre-dilatation and post-dilatation AS-OCT images, using the internal caliper of the device from the scleral spur (SS) level (AST-0) and 1000 μm (AST-1) and 2000 μm (AST-2) posterior to SS level. Scleral thickness was measured as the distance between the low reflective band under the conjunctiva (the episcleral vessels) and the low reflective band at the posterior border of sclera (ciliary muscle). ACAF values were measured three times consecutively for both pre-dilatation and post-dilatation measurements by the same investigator (AG) and the average of these measurements were noted. Also the measurements were made at the same hours of the day (between 08.00 and 09.00 am) to eliminate diurnal variations. All manual measurements from the AS-OCT images were made by two investigators (AG, MEB) separately, three measurements were taken for each localization and mean values of 6 measurements were used for analysis. Inter- and intra-observer variability were assessed using the intraclass correlation coefficient (ICC) from 10 randomly selected measurements. Intra-observer ICC were above 0.90 for AST-0, AST-1 and AST-2. Inter-observer ICC were 0.86, 0.89 and 0.80 respectively for AST-0, AST-1 and AST-2. The investigators were not masked to pre- and post-treatment status of the patients. IBM SPSS Statistics 25.0 (IBM SPSS Statistics for Windows, Version 25.0.; IBM Corp., Armonk, NY) was used for statistical analysis. Descriptive statistics were given as mean, standard deviation, minimum, and maximum. For comparison of the mean values of parameters before and after Mydfrin® instillation, The Wilcoxon test was used. P values less than 0.05 was considered as statistically significant. Post-hoc power analysis was performed for the primary outcome measures to evaluate the achieved statistical power of the study. Effect sizes for paired comparisons were calculated using Cohen’s dz. The achieved power (1–β) was calculated based on the observed effect sizes, sample size, and a two-tailed alpha level of 0.05. Results Right eyes of 20 (7 female and 13 male) participants were included. Mean age of the participants was 31.3 ± 7.2 (25–45) years. The mean BCVA was 20/20 and mean IOP was 16.7 ± 3.4 (13–21) mmHg. No pathology was observed in the anterior and posterior segment examinations. Iris color was blue/green in 5 (25%) eyes, dark brown in 6 (30%) eyes, and brown in 9 (45%) eyes. Both nasal and temporal anterior scleral thickness were increased in post-dilatation measurements compared to pre-dilatation measurements in SS level (AST-0), whereas AST-1 and AST-2 were decreased. The pre-phenylephrine and post-phenylephrine values of nasal and temporal AST-0, AST-1, AST-2 levels and ACAF levels are displayed in Table 1. Comparison of pre- and post-dilation values between study and control eyes are summarized in Table 2. Table 1Comparison of pre- and post- pupillary dilatation anterior scleral thickness measurements and aqueous humor flare valuesMeasurementsStudy EyesControl EyesPre-dilatationPost-dilatationP valuePre-dilatationPost-dilatationP value AST-0, µm, mean ± SD (min-max) - Nasal638.2 ± 39.6(563–721)662.6 ± 36.1(580–738)0.0003661 ± 36.4(597–745)660.8 ± 42.2(601–780)0.9 - Temporal683.6 ± 24.3(621–734)699.3 ± 32.8(605–754)0.01698.9 ± 33.8(615–741)698.2 ± 38.0(612–745)0.71 AST-1, µm, mean ± SD (min-max) - Nasal551.8 ± 35.4(480–616)539.1 ± 41.0(461–580)0.06563.5 ± 39.4(495–631)561.3 ± 35.8(497–635)0.28 - Temporal576 ± 37.9(513–656)551.0 ± 42.9(468–639)0.005545.1 ± 35.8(482–616)548.4 ± 41.4(469–620)0.62 AST-2, µm, mean ± SD (min-max) - Nasal570 ± 45.7(502–652)551.4 ± 38.0(512–631)0.01582.6 ± 43.9(530–665)579.7 ± 46.7(526–670)0.84 - Temporal565 ± 43.4(497–653)553.9 ± 43.3(472–639)0.18563 ± 29.6(522–618)561.9 ± 27.7(530–620)0.74 ACAF, photon/ms 1.6 ± 2.0(0-5.8)2.6 ± 4.3(0–42)0.21.3 ± 1.7(0-6.2)2.1 ± 3.8(0-12.7)0.83AST-0: anterior scleral thickness at the scleral spur levelAST-1: anterior scleral thickness 1000 μm behind the scleral spurAST-2: anterior scleral thickness 2000 μm behind the scleral spurACAF: Anterior chamber aqueous flareSD: Standard deviation, pre-dilatation: before phenylephrine 2.5%, post-dilatation: 45 min after phenylephrine 2.5% instillationms: millisecond Table 1Comparison of pre- and post- pupillary dilatation anterior scleral thickness measurements and aqueous humor flare valuesMeasurementsStudy EyesControl EyesPre-dilatationPost-dilatationP valuePre-dilatationPost-dilatationP value AST-0, µm, mean ± SD (min-max) - Nasal638.2 ± 39.6(563–721)662.6 ± 36.1(580–738)0.0003661 ± 36.4(597–745)660.8 ± 42.2(601–780)0.9 - Temporal683.6 ± 24.3(621–734)699.3 ± 32.8(605–754)0.01698.9 ± 33.8(615–741)698.2 ± 38.0(612–745)0.71 AST-1, µm, mean ± SD (min-max) - Nasal551.8 ± 35.4(480–616)539.1 ± 41.0(461–580)0.06563.5 ± 39.4(495–631)561.3 ± 35.8(497–635)0.28 - Temporal576 ± 37.9(513–656)551.0 ± 42.9(468–639)0.005545.1 ± 35.8(482–616)548.4 ± 41.4(469–620)0.62 AST-2, µm, mean ± SD (min-max) - Nasal570 ± 45.7(502–652)551.4 ± 38.0(512–631)0.01582.6 ± 43.9(530–665)579.7 ± 46.7(526–670)0.84 - Temporal565 ± 43.4(497–653)553.9 ± 43.3(472–639)0.18563 ± 29.6(522–618)561.9 ± 27.7(530–620)0.74 ACAF, photon/ms 1.6 ± 2.0(0-5.8)2.6 ± 4.3(0–42)0.21.3 ± 1.7(0-6.2)2.1 ± 3.8(0-12.7)0.83AST-0: anterior scleral thickness at the scleral spur levelAST-1: anterior scleral thickness 1000 μm behind the scleral spurAST-2: anterior scleral thickness 2000 μm behind the scleral spurACAF: Anterior chamber aqueous flareSD: Standard deviation, pre-dilatation: before phenylephrine 2.5%, post-dilatation: 45 min after phenylephrine 2.5% instillationms: millisecond Comparison of pre- and post- pupillary dilatation anterior scleral thickness measurements and aqueous humor flare values 638.2 ± 39.6 (563–721) 662.6 ± 36.1 (580–738) 661 ± 36.4 (597–745) 660.8 ± 42.2 (601–780) 683.6 ± 24.3 (621–734) 699.3 ± 32.8 (605–754) 698.9 ± 33.8 (615–741) 698.2 ± 38.0 (612–745) 551.8 ± 35.4 (480–616) 539.1 ± 41.0 (461–580) 563.5 ± 39.4 (495–631) 561.3 ± 35.8 (497–635) 576 ± 37.9 (513–656) 551.0 ± 42.9 (468–639) 545.1 ± 35.8 (482–616) 548.4 ± 41.4 (469–620) 570 ± 45.7 (502–652) 551.4 ± 38.0 (512–631) 582.6 ± 43.9 (530–665) 579.7 ± 46.7 (526–670) 565 ± 43.4 (497–653) 553.9 ± 43.3 (472–639) 563 ± 29.6 (522–618) 561.9 ± 27.7 (530–620) 1.3 ± 1.7 (0-6.2) 2.1 ± 3.8 (0-12.7) AST-0: anterior scleral thickness at the scleral spur level AST-1: anterior scleral thickness 1000 μm behind the scleral spur AST-2: anterior scleral thickness 2000 μm behind the scleral spur ACAF: Anterior chamber aqueous flare SD: Standard deviation, pre-dilatation: before phenylephrine 2.5%, post-dilatation: 45 min after phenylephrine 2.5% instillation ms: millisecond Table 2The significance of difference of pre- and post- dilatation anterior scleral thickness measurements and aqueous humor flare values between the study and the control groupsPre-dilatation differencePost- dilatation difference AST-0, p value - Nasal0.070.6 - Temporal0.010.86 AST-1, p value - Nasal0.20.01 - Temporal0.080.8 AST-2, p value - Nasal0.310.01 - Temporal0.80.46ACAF, p value0.30.4AST-0: anterior scleral thickness at the scleral spur levelAST-1: anterior scleral thickness 1000 μm behind the scleral spurAST-2: anterior scleral thickness 2000 μm behind the scleral spurACAF: Anterior chamber aqueous flareSD: Standard deviation, pre-dilatation: before phenylephrine 2.5%, post-dilatation: 45 min after phenylephrine 2.5% instillation Table 2The significance of difference of pre- and post- dilatation anterior scleral thickness measurements and aqueous humor flare values between the study and the control groupsPre-dilatation differencePost- dilatation difference AST-0, p value - Nasal0.070.6 - Temporal0.010.86 AST-1, p value - Nasal0.20.01 - Temporal0.080.8 AST-2, p value - Nasal0.310.01 - Temporal0.80.46ACAF, p value0.30.4AST-0: anterior scleral thickness at the scleral spur levelAST-1: anterior scleral thickness 1000 μm behind the scleral spurAST-2: anterior scleral thickness 2000 μm behind the scleral spurACAF: Anterior chamber aqueous flareSD: Standard deviation, pre-dilatation: before phenylephrine 2.5%, post-dilatation: 45 min after phenylephrine 2.5% instillation The significance of difference of pre- and post- dilatation anterior scleral thickness measurements and aqueous humor flare values between the study and the control groups AST-0: anterior scleral thickness at the scleral spur level AST-1: anterior scleral thickness 1000 μm behind the scleral spur AST-2: anterior scleral thickness 2000 μm behind the scleral spur ACAF: Anterior chamber aqueous flare SD: Standard deviation, pre-dilatation: before phenylephrine 2.5%, post-dilatation: 45 min after phenylephrine 2.5% instillation Post-hoc power analysis demonstrated high achieved power for anterior scleral thickness changes at the scleral spur level (AST-0 nasal, 1–β = 0.99; AST-1 temporal, 1–β = 0.89). The achieved power for aqueous flare measurements was 0.05, suggesting a likely minimal effect size rather than a definitive absence of effect. (Cohen’s dz = 0.02). Discussion In the present study, the use of topical phenylephrine 2.5% in healthy eyes was associated with thickening of sclera at SS level, and thinning of the sclera at 1000 µm and 2000 μm behind the SS. Scleral thickening was significant at the nasal and temporal SS levels. The thinning of the sclera was only significant at 1000 μm posterior to the temporal SS level. Topical application of phenylephrine 2.5% did not significantly alter the ACAF values in healthy eyes. Application of topical phenylephrine to the right eyes, did not have a significant effect on the left eyes in terms of AST at all levels and aqueous flare levels. To our surprise, there was a significant difference in pre-dilation temporal AST-0 values between right and left eyes (study and control eyes) of the same individuals. This unexpected inter-eye difference represents a potential source of bias. In the literature, the biometric features such as central corneal thickness, axial length, corneal curvature and anterior chamber depth of healthy eyes are usually symmetrical in the same individual [3]. However, there are studies reporting variability of intraocular pressure fluctuations between the two eyes, in both healthy eyes and eyes with glaucoma [3–6]. This asymetry in scleral thickness between right and left eyes might be due to many factors that need to be investigated, such as the increased microvascular flow in dominant eye or asymmetrical IOP fluctuations between the two eyes. Further studies with larger sample size and additional imaging technics are needed. Accomodation is an adaptive mechanism of human eye to achieve a clear near vision. The contraction of the ciliary muscle results with relaxation of lens zonules and an increased lens thickness, which increases the total refractive power. To eliminate accomodation during pediatric refractive examinations, most clinicians use a combination of tropicamide, cyclopentolate and phenylephrine (TCP) [7]. In this combination, phenylephrine, a sympathomimetic, is used for achieving maximal mydriasis by constricting the iris dilatator muscle. Its primary area of impact is alpha-1 adrenergic agonists and it has little to no effect on beta adrenergic agonists [8]. There are many studies and reports that question the necessity of phenylephrine in this commonly used TCP combination. The “Brazilian guideline for pediatric cycloplegia and mydriasis” suggest the use of cyclopentolate 1% and tropicamide 1% combination for refractive evaluation in patients older than 6 months old. The same guideline recommended the use of 2.5% phenylephrine as an adjuvant only if the extreme periphery of the retina needs to be visualised or if poor mydriasis is present [8]. In another report, the authors declared that they achieved a better mydriasis in patients when phenylephrine was not used [9]. On the contrary, Sherman et al. reported that they achieved equal cycloplegia in both TCP and CP applied eyes and a mydriasis sufficient for detailed fundoscopic examination [7]. Routine tropicamide use for refractive examination was not found as mandatory or effective in their study. However, in the present study, the finding of the thickening of the sclera at SS level, may suggest an indirect effect on ciliary muscle configuration or scleral biomechanics. Phenylephrine’s inhibition of ciliary muscle constriction might inhibit the forward and inward movement of the ciliary muscle with its adjacent sclera and might prevent it from thinning by the traction force. Scleral thickness at 1000 μm and 2000 away from SS levels, were thinner after phenylephrine application. This might also support that phenyleprine’s possible effect on ciliary muscle also has an impact on scleral biomechanics. In a previous study with cyclopentolate eye drops, we similarly observed that scleral thickness was increased at SS level but decreased in AST-1 and AST-2 locations [10]. To the best of our knowledge, this is the first study to demonstrate the effects of topical phenylephrine 2.5% application on scleral thickness. In this study, ACAF levels in healthy eyes were found as increased after application of phenylephrine but the effect was not significant. This is the first study in the literature to evaluate the effect of phenylephrine eye drops alone, on ACAF levels. The pre-phenylephrine levels of ACAF in healthy eyes were similar with the literature [11, 12]. In previous studies, mydriatic agents were reported to cause a decrease in ACAF levels in both healthy and anterior uveitic eyes, due to the reduction of blood aqueous barrier permeability [12, 13]. Ikeji et al. reported that in their study with anteiror uveitic eyes, pupillary dilatation with TP combination decreased the ACAF levels, but the effect was not significant [14]. Contrary to that report, tropicamide was reported to cause an increase in ACAF levels, in eyes with pseudoexfoliation syndrome, a different condition with altered blood aqueous barrier permeability [15]. It was previously shown that ACAF levels increase and the accomodation amplitude decreases with age. In the present study, all participants were between 25 and 45 years of ages, which is a factor that might help minimizing the age related changes. In conclusion, topical phenylephrine 2.5% was associated with localized alterations in anterior scleral thickness, characterized by thickening at the scleral spur level and relative thinning posterior to this region. These findings may be associated with changes in ciliary muscle configuration and scleral biomechanics, although the exact underlying mechanisms remain unclear. Importantly, aqueous flare levels showed no statistically significant change following phenylephrine administration. Given the very low statistical power for this outcome, this finding should be interpreted cautiously and may reflect a minimal effect size rather than a definitive absence of effect. From a clinical perspective, the observed changes in scleral thickness may have implications for the interpretation of anterior segment imaging and for understanding the biomechanical effects of commonly used mydriatic agents. However, the lack of a measurable effect on aqueous flare suggests that phenylephrine alone is unlikely to have a clinically meaningful impact on intraocular inflammatory status in healthy eyes. This study has several limitations. The relatively small sample size and the use of the fellow eye as a control group may introduce bias due to potential inter-eye asymmetry. In addition, observers were not masked to pre- and post-treatment status, which may have influenced measurements. The lack of quantitative assessment of pupillary dilation is another limitation. Despite these limitations, this study represents, to the best of our knowledge, the first report demonstrating the effects of topical phenylephrine on anterior scleral thickness. Further studies with larger sample sizes and comparative evaluation of different mydriatic agents are warranted to better understand the clinical significance of these findings.